NCT01445028View on ClinicalTrials.gov

Isotretinoin for Proliferative Vitreoretinopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2015

Conditions
Proliferative Vitreoretinopathy
Interventions
DRUG

Isotretinoin

Isotretinoin 20mg daily for 12 weeks

Trial Locations (1)

19107

Wills Eye Institute, Philadelphia

All Listed Sponsors
lead

Wills Eye

OTHER

NCT01445028 - Isotretinoin for Proliferative Vitreoretinopathy | Biotech Hunter | Biotech Hunter